Analysis Of The Efficacy Of Imatinib Mesylate In The Preoperative Treatment Of High Risk Gastrointestinal Stromal Tumors

Objective:To investigate the effect of imatinibi mesylate in the treatment of high risk gastrointestinal stromal tumors(gist)and its influence on the prognosis of the patients.Methods: The baseline data of 54 patients with high risk gastrointestinal stromal tumors admitted to the Xinjiang Medical University from June 2011 to June 2016 were analyzed retrospectively,according to whether the patients were treated with imatinibi mesylate before operation,they were divided into two groups: Control Group(24)and trial group(30).The data of preoperative,intraoperative,postoperative and follow-up were collected and analyzed by SPSS22.0 statistical software.Results:1.The average operation time(127.3325.45)Min,the average blood loss(89.3343.06)ML,the average hospital stay(9.102.00)days in the experimental group were shorter than those in the Control Group(156.4635.59)Min,the average blood loss(135.4282.72)ml and the average hospital stay(11.212.46)days,the difference between the two groups was statistically significant.2.The number of Ro resections in the experimental group(27)was more than that in the Control Group(15).3.The average resection range of the experimental group was(8.151.76)cm,which was significantly smaller than that of the control group(9.572.45)cm.4.The difference between preoperative and postoperative maximum tumor diameter(3.47-1.37 cm)in the experimental group was significantly higher than that in the Control Group(1.150.95 cm).5.The number of combined splanchnic resection in the test group(3)was less than that in the Control Group(9).The difference between the two groups was significant.6.The 3-year recurrence or metastasis rate(0.33)in the experimental group was lower than that in the control group(0.63),and the difference between the two groups was statistically significant.Kill.The time of recurrence or metastasis in the experimental group was about 24 months later than that in the control group,which wasabout 18 months later than that in the control group.Conclusion: Imatinib mesylate as an adjuvant therapy can significantly improve the outcome and prognosis of primary high-risk gastrointestinal stromal tumors.